The Influence of High Body Mass Index (BMI > 35 kg/m2) on Apixaban Plasma Concentration in Patients with Atrial Fibrillation
BMI ≥ 35 kg/m<sup>2</sup> patients exhibited lower apixaban trough concentrations, while remaining within the manufacturer's established range for effective steady-state apixaban, suggesting that dose adjustment is unnecessary for this specific patient group.
Authors
- Kerstin Carlin Ram
- Orli Shimoni
- Harel Eitam
- Gilat Ron Avraham
- Raul Colodner (ORCID: https://orcid.org/0000-0001-9752-1053)
- Eyal Schwartzberg (ORCID: https://orcid.org/0000-0002-8588-7223)
- Mariana Issawy (ORCID: https://orcid.org/0009-0000-2269-8292)
- May Hilu
- Lee H. Goldstein (ORCID: https://orcid.org/0000-0003-1379-6012)
- Mazen Elias
Institutions
- Ben-Gurion University of the Negev (IL)
- Technion – Israel Institute of Technology (IL)
- Emek Medical Center (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- American Journal of Cardiovascular Drugs
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1007/s40256-024-00678-w
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Technion-Israel Institute of Technology